Qpex Biopharma

San Diego, United States Founded: 2018 • Age: 8 yrs Acquired By Shionogi
Therapies for infectious diseases are developed using beta-lactamase inhibitor technology.
Request Access

About Qpex Biopharma

Qpex Biopharma is a company based in San Diego (United States) founded in 2018 was acquired by Shionogi in June 2023.. Qpex Biopharma has raised $33 million across 1 funding round from investors including Shionogi, NEA and Adams Street Partners. The company has 12 employees as of December 31, 2022. Qpex Biopharma offers products and services including Antibiotics Development and Enzyme Inhibition Therapies. Qpex Biopharma operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.

  • Headquarter San Diego, United States
  • Employees 12 as on 31 Dec, 2022
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Qpex Biopharma, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $33 M (USD)

    in 1 rounds

  • Latest Funding Round
    $33 M (USD), Series A

    Jul 31, 2019

  • Investors
    Shionogi

    & 4 more

  • Employee Count
    12

    as on Dec 31, 2022

  • Acquired by
    Shionogi

    (Jun 25, 2023)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Qpex Biopharma

Qpex Biopharma offers a comprehensive portfolio of products and services, including Antibiotics Development and Enzyme Inhibition Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Creates new antibiotics to target drug-resistant pathogens effectively.

Develops therapies to inhibit enzymes and restore antibiotic potency.

People of Qpex Biopharma
Headcount 10-50
Employee Profiles 7
Employee Profiles
People
Michael N. Dudley
President & CEO
People
Jeff Loutit
Chief Medical Officer
People
Wendy Roos
VP, Finance, Administration & Controller
People
Michelle Linfesty
VP, Program Management

Unlock access to complete

Funding Insights of Qpex Biopharma

Qpex Biopharma has successfully raised a total of $33M through 1 strategic funding round. The most recent funding activity was a Series A round of $33 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series A — $33.0M
  • First Round

    (31 Jul 2019)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2019 Amount Series A - Qpex Biopharma Valuation New Enterprise Associates
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Qpex Biopharma

Qpex Biopharma has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Shionogi, NEA and Adams Street Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital investments are offered to startups by NEA.
Founded Year Domain Location
Private markets investment management with strategies in equity, credit, and secondary investments.
Founded Year Domain Location
A global healthcare-focused VC/PE firm is operated.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Qpex Biopharma

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Qpex Biopharma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Qpex Biopharma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Qpex Biopharma

Qpex Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics for drug-resistant bacterial infections are developed.
domain founded_year HQ Location
Pleuromutilin antibiotics are developed for MDR infections.
domain founded_year HQ Location
Developer of bacterial ribosome-targeting drugs for MDR infections
domain founded_year HQ Location
Developer of antibiotics for MDR infections
domain founded_year HQ Location
Therapies for multi-drug resistant infections are developed using bacteriophages.
domain founded_year HQ Location
Therapeutics for antimicrobial resistant infections are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Qpex Biopharma

When was Qpex Biopharma founded?

Qpex Biopharma was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Qpex Biopharma located?

Qpex Biopharma is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Who is the current CEO of Qpex Biopharma?

Michael Dudley is the current CEO of Qpex Biopharma.

Is Qpex Biopharma a funded company?

Qpex Biopharma is a funded company, having raised a total of $33M across 1 funding round to date. The company's 1st funding round was a Series A of $33M, raised on Jul 31, 2019.

How many employees does Qpex Biopharma have?

As of Dec 31, 2022, the latest employee count at Qpex Biopharma is 12.

What does Qpex Biopharma do?

Qpex Biopharma was founded in 2018 and is based in San Diego, United States. Operations focus on the biopharma sector, where therapies for infectious diseases are advanced. Proprietary beta-lactamase inhibitor technology is employed to develop antibiotics that address drug-resistant and gram-negative infections. Undisclosed anti-infective candidates are being progressed through this platform to tackle unmet needs in antimicrobial treatment.

Who are the top competitors of Qpex Biopharma?

Qpex Biopharma's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.

What products or services does Qpex Biopharma offer?

Qpex Biopharma offers Antibiotics Development and Enzyme Inhibition Therapies.

Who are Qpex Biopharma's investors?

Qpex Biopharma has 5 investors. Key investors include Shionogi, NEA, Adams Street Partners, LYZZ Capital, and Hatteras Venture Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available